Results 221 to 230 of about 3,377,180 (268)

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Peptides, 2020
Accumulating evidence suggests that glucose-dependent insulinotropic polypeptide (GIP) in addition to its involvement in type 2 diabetic pathophysiology may be involved in the development of obesity and the pathogenesis of cardiovascular disease. In this review, we outline recent preclinical and clinical cardiovascular-related discoveries about GIP ...
Sebastian M. Heimbürger, Natasha C. Bergmann, Robert Augustin, Lærke S. Gasbjerg, Mikkel B. Christensen, Filip K. Knop   +5 more
openaire   +3 more sources

Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

Best Practice & Research Clinical Endocrinology & Metabolism, 2004
The 42 amino acid polypeptide glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) is released from intestinal K-cells in response to nutrient ingestion. Based on animal studies, the peptide was initially assumed to act as an endogenous inhibitor of gastric acid secretion.
Juris J. Meier, Michael A. Nauck
openaire   +1 more source

Glucose-dependent insulinotropic polypeptide and its role in obesity

Current Opinion in Endocrinology, Diabetes & Obesity, 2007
As we strive to improve our understanding of the factors that contribute to the pathogenesis of obesity, it is certainly logical to speculate that a nutrition-dependent component emanating from the gastrointestinal tract, which has the capacity to regulate insulin expression, could represent an etiologic factor in this serious health issue.
Diane H, Song, M Michael, Wolfe
openaire   +2 more sources

Glucose-dependent insulinotropic polypeptide – beyond the enteroinsular axis?

Current Opinion in Endocrinology and Diabetes, 2006
Purpose of review: Glucose-dependent insulinotropic polypeptide (GIP) plays an important role in the enteroinsular axis, stimulating insulin secretion. In addition, it has extrapancreatic actions, which may have pathophysiological relevance. This review highlights recent findings with regard to GIP's actions both within the enteroinsular axis and ...
Robertson, MD, Johnston, KL, Morgan, LM
openaire   +3 more sources

Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders

Expert Opinion on Therapeutic Targets, 2018
Incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) exert pleiotropic effects on endocrine pancreas and nervous system. Expression of GIP and GIP receptor (GIPR) in neurons, their roles in neurogenesis, synaptic plasticity, neurotransmission, and neuromodulation uniquely position GIPR for ...
Nandakumar K, Mahip Verma, Kumar Nemmani   +2 more
exaly   +3 more sources

Central Regulation of Glucose-Dependent Insulinotropic Polypeptide Secretion

2010
Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are potent stimulators of glucose-dependent insulin secretion, a phenomenon known as incretin effect. After food ingestion, the circulating levels of GIP and GLP-1 rise more quickly than could be explained by the arrival of unabsorbed nutrients that have a direct ...
Maria P, Yavropoulou, John G, Yovos
openaire   +2 more sources

Safety of native glucose-dependent insulinotropic polypeptide in humans

Peptides
In this systematic review, we assessed the safety and possible safety events of native glucose-dependent insulinotropic polypeptide (GIP)(1-42) in human studies with administration of synthetic human GIP. We searched the PubMed database for all trials investigating synthetic human GIP(1-42) administration. A total of 67 studies were included.
Helsted, Mads M., Schaltz, Nina L., Gasbjerg, Lærke S., Christensen, Mikkel B., Vilsbøll, Tina, Knop, Filip K.   +5 more
openaire   +3 more sources

The pharmacokinetics of porcine glucose‐dependent insulinotropic polypeptide (GIP) in man

European Journal of Clinical Investigation, 1982
Abstract. The pharmacokinetics of porcine glucose‐dependent insulinotropic polypeptide were investigated in six healthy volunteers. At the maximum infusion dose (0·5 pmol kg‐1 min‐1) a plateau concentration of 115 ± 5·0 pmol/l plasma was obtained. On discontinuation of the infusion, the half‐time of disappearance was calculated to be 20·3 ± 1·2 min ...
D L, Sarson, R C, Hayter, S R, Bloom
openaire   +2 more sources

Functional analysis of glucose-dependent insulinotropic polypeptide fusion proteins

Peptides, 2001
To generate functional fluorescently tagged glucose-dependent insulinotropic polypeptide (GIP), a series of GIP expression constructs were devised. These included G1 (complete preprohormone), G2 (lacking the C-terminal extension), G3 (lacking both N- and C-terminal extensions), G4 (G2 fused to green fluorescent protein, GFP), and G5 (G3 fused to GFP ...
K H, Ding, C M, Isales, Q, Zhong, R J, Bollag   +3 more
openaire   +2 more sources

Evolution of the vertebrate glucose-dependent insulinotropic polypeptide (GIP) gene

Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2006
The glucose-dependent insulinotropic polypeptide (GIP) gene is believed to have originated from a gene duplication event very early in vertebrate evolution that also produced the proglucagon gene, yet so far GIP has only been described within mammals. Here we report the identification of GIP genes in chicken, frogs, and zebrafish.
David M, Irwin, Tony, Zhang
openaire   +2 more sources